Patents Assigned to Hoffmann-La Roche Inc.
  • Publication number: 20210163617
    Abstract: The present invention relates to combination therapies employing a 4-1BB agonist comprising at least one antigen binding domain capable of specific binding to tumor-associated antigen in combination with specific antibodies which bind human CD20 and the use of these combination therapies for the treatment of cancer.
    Type: Application
    Filed: September 10, 2020
    Publication date: June 3, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Claudia FERRARA KOLLER, Christian KLEIN, Johannes SAM, Pablo UMANA, Wei XU
  • Publication number: 20210163626
    Abstract: The invention provides anti-variant Fc-region antibodies which specifically bind to an antibody that has the mutation P329G or the mutations P329G/L234A/L235A or the mutations 1253A/H310A/H435A in the Fc-region, and methods of using the same.
    Type: Application
    Filed: December 7, 2020
    Publication date: June 3, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Frank Kowalewsky, Mirko Ritter, Kay-Gunnar Stubenrauch, Uwe Wessels
  • Patent number: 11021503
    Abstract: The invention comprises a process for the preparation of therapeutically valuable GalNAc cluster oligonucleotide conjugates. The process comprises the coupling of an alkali metal salt, earth alkali metal salt or a tetraalkylammonium salt of an oligonucleotide with a GalNAc cluster compound or with a salt thereof and a subsequent purification.
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: June 1, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Simon Breitler, Joerg Lill, Kurt Puentener, René Trussardi
  • Patent number: 11021728
    Abstract: Herein is reported a method for the production of an immunoglobulin comprising the following steps: a) providing a eukaryotic cell comprising a nucleic acid encoding the immunoglobulin, b) cultivating the eukaryotic cell in a cultivation medium wherein the amount of glucose available in the cultivation medium per time unit is kept constant and limited to less than 80% of the amount that could maximally be utilized by the cells in the cultivation medium per time unit, and c) recovering the immunoglobulin from the culture.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: June 1, 2021
    Assignees: Hoffmann-La Roche Inc., Chugai Seiyaku Kabushiki Kaisha
    Inventors: Reinhard Franze, Chikashi Hirashima, Thomas Link, Yoshinori Takagi, Shinya Takuma, Yuriko Tsuda
  • Patent number: 11021448
    Abstract: The present invention provides compounds that are muscarinic M1 receptor positive allosteric modulators (PAM) and useful in the treatment of diseases, mediated by the muscarinic M1 receptor, such as Alzheimer's disease, cognitive impairment, schizophrenia, pain or sleep disorders, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: June 1, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventor: Alexander Flohr
  • Publication number: 20210155655
    Abstract: Herein is reported a method for the purification of a protein comprising erythropoietin and a single poly (ethylene glycol) residue from reaction by-products or not reacted starting material by a cation exchange chromatography method. It has been found that by employing a cation exchange Toyopearl® SP-650 chromatography material and employing a second wash step with an increased pH value compared to the first wash step a fusion protein of erythropoietin and a single poly (ethylene glycol) residue can be obtained in a single step with high purity and yield and suitability for large scale applications.
    Type: Application
    Filed: January 11, 2021
    Publication date: May 27, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: ROBERTO FALKENSTEIN, BERNHARD SPENSBERGER
  • Publication number: 20210155656
    Abstract: Herein is reported a method for purifying a protein from a sample comprising the protein and at least one impurity with hydrolytic activity, comprising the following steps: i) a) applying the sample comprising the protein and at least one impurity with hydrolytic activity to a chromatography material, b) applying a solution which comprises a polysorbate to the chromatography material, and c) recovering the protein from the chromatography material, or ii) a) adding a polysorbate to the sample comprising the protein and at least one impurity with hydrolytic activity, b) applying the mixture of step a) to a chromatography material, and c) recovering the protein from the chromatography material, or iii) a) adding a polysorbate to the sample comprising the protein and at least one impurity with hydrolytic activity, b) applying the mixture of step a) to a chromatography material, c) applying a solution which comprises a polysorbate to the chromatography material, and d) recovering the protein from the chr
    Type: Application
    Filed: October 26, 2020
    Publication date: May 27, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Roberto FALKENSTEIN, Michael LEISS, Bernhard SPENSBERGER, Satya Krishna Kishore RAVURI
  • Patent number: 11013801
    Abstract: The present invention relates to methods of treating a disease, and methods for reduction of the formation of anti-drug antibodies (ADAs) in response to the administration of a therapeutic agent. The invention further relates to methods of treating a disease, particularly a B-cell proliferative disorder, and methods for reduction of adverse effects in response to the administration of a therapeutic agent, particularly a T-cell activating therapeutic agent.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: May 25, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marina Bacac, Stefan Evers, Christian Klein, Pavel Pisa, Eva Rossmann, Jose Saro, Pablo Umana
  • Patent number: 11014963
    Abstract: The invention provides novel compounds having the general formula (I) wherein R2, R3, R4, R5, R6, R7, R3, R8, R10, R11 and R23 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: September 4, 2018
    Date of Patent: May 25, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Benoit Hornsperger, Roberto Iacone, Hans P. Maerki, Peter Mohr, Michael Reutlinger
  • Patent number: 11017533
    Abstract: The system is configured to receive at least one digital image of a tissue sample of a patient; analyze the at least one received image for identifying tumor cells in a region of the at least one received image; analyze the at least one received image for identifying FAP+ areas in the region, each FAP+ area being a pixel blob representing one or more cells express the fibroblast activation protein—“FAP”; analyze the at least one received image for identifying distances between the identified tumor cells and their respective nearest FAP+ area; computing a proximity measure as a function of the identified distances; process the proximity measure by a classifier for generating a classification result, the classification result indicating if the tumor of the patient can be treated by a drug or drug-component that binds to FAP; and output the classification result.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: May 25, 2021
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Fabien Gaire, Oliver Grimm, Hadassah Sumum Sade, Suzana Vega Harring
  • Publication number: 20210147553
    Abstract: The present invention relates to anti-HLA-G antibodies and methods of using the same.
    Type: Application
    Filed: October 16, 2020
    Publication date: May 20, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stefan DENGL, Sebastian FENN, Jens FISCHER, Andreas HINZ, Claudia KIRSTENPFAD, Stefan KLOSTERMANN, Joerg MOELLEKEN, Georg TIEFENTHALER, Sabine HOVES, Alexander BUJOTZEK, Meher MAJETY
  • Publication number: 20210147447
    Abstract: The present invention provides compounds of formula (I) wherein A, R1, R2 and R3 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments.
    Type: Application
    Filed: November 16, 2020
    Publication date: May 20, 2021
    Applicants: Hoffmann-La Roche Inc., PTC Therapeutics, Inc.
    Inventors: Hasane Ratni, Luke Green, Marla L. Weetall, Nikolai A. Naryshkin
  • Publication number: 20210147554
    Abstract: The present invention relates to multispecific antibodies that bind to HLA-G ant to a T cell activating antigen, their preparation, formulations and methods of using the same.
    Type: Application
    Filed: October 16, 2020
    Publication date: May 20, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stefan DENGL, Sebastian FENN, Jens FISCHER, Claudia KIRSTENPFAD, Stefan KLOSTERMANN, Joerg MOELLEKEN, Georg TIEFENTHALER, Alexander BUJOTZEK, Meher MAJETY, Silke KIRCHNER
  • Publication number: 20210138065
    Abstract: The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with a CD79b antibody-drug conjugate for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and a CD79b antibody-drug conjugate.
    Type: Application
    Filed: December 18, 2020
    Publication date: May 13, 2021
    Applicants: HOFFMANN-LA ROCHE INC., GENENTECH, INC.
    Inventors: Christian KLEIN, Sabine LANG, Pablo UMANA, Andrew G. POLSON
  • Publication number: 20210139561
    Abstract: Disclosed herein, in part, are methods for the expression and production of a trivalent, bispecific antibody using a recombinant nucleic acid comprising multiple, different expression cassettes in a specific and defined sequence, which are stably integrated into the genome of a mammalian cell.by targeted integration.
    Type: Application
    Filed: June 19, 2020
    Publication date: May 13, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Johannes AUER, Simon AUSLAENDER, Monika FRUEHSCHUETZ, Ulrich GOEPFERT, Heidi HARBECK-JANSSEN, Christina-Lisa HOECK
  • Publication number: 20210139576
    Abstract: The current invention relates to the use of antibodies which bind to VEGF and ANG2 for the treatment of ophthalmologic diseases.
    Type: Application
    Filed: August 5, 2020
    Publication date: May 13, 2021
    Applicants: Hoffmann-La Roche Inc., Genentech, Inc.
    Inventors: Aaron Osborne, Jayashree Sahni, Robert James Weikert
  • Publication number: 20210130334
    Abstract: The invention relates to a compound of formula (I) wherein A1 and R1-R4 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: December 17, 2020
    Publication date: May 6, 2021
    Applicants: HOFFMANN-LA ROCHE INC., EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH
    Inventors: Simon M. Ametamey, Luca Gobbi, Uwe Grether, Julian Kretz
  • Publication number: 20210122832
    Abstract: Herein is reported a multispecific antibody comprising two circular fusion polypeptides each of them comprising a VH/VL-pair and thereby a first and a second binding site, whereby a third VH/VL-pair and thereby a third binding site is formed by the associated of the two circular fusion polypeptides.
    Type: Application
    Filed: April 29, 2020
    Publication date: April 29, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Steffen Dickopf, Guy Georges, Irmgard Thorey
  • Publication number: 20210122743
    Abstract: The present invention relates to a compound of formula and to a pharmaceutically suitable acid addition salt thereof with a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1, for the treatment of certain CNS diseases.
    Type: Application
    Filed: June 11, 2020
    Publication date: April 29, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Guido GALLEY, Marius HOENER, Roger NORCROSS, Philippe PFLIEGER
  • Publication number: 20210123019
    Abstract: Herein is reported a method for co-cultivating one or more B-cells comprising the step of incubating the one or more B-cells with EL4-B5 cells, whereby the EL4-B5 cells have been obtained/are from a cultivation of EL4-B5 cells that has a cell density of from 600,000 cells/ml up to 1,500,000 cells/ml.
    Type: Application
    Filed: December 3, 2020
    Publication date: April 29, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Sonja Offner, Friederike Jung